Cash, cash equivalents and marketable securities were $360.0 million as of December 31, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash, cash equivalents and marketable securities will fund operations into 2028 based on its current business plan.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
- Maze Therapeutics adds Neil Kumar to board leadership
- Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- Maze Therapeutics initiated with a Buy at Truist
- Maze Therapeutics price target raised to $58 from $43 at Wedbush